A Study of Teduglutide in Japanese Children With Short Bowel Syndrome Aged 4 Months or Older

NCT05027308 | Completed Phase 3 Results FDA Drug

• 4 other identifiers: TAK-633-3008U1111-1267-3327jRCT20212100352022-003572-16
• Study Type: interventional
• Target: 3
• Locations: 1 country
• Sites: 6

Brief Summary

The main aims of the study are to check for side effects from teduglutide. Participants will receive a daily injection of teduglutide just under the skin (subcutaneous) for 24 weeks. Then they are followed up for another 4 weeks. Participants may be able to repeat this treatment if they meet specific criteria. The study doctors will check for side effects from teduglutide until it becomes commercially available. The maximum duration of treatment is approximately 51.3 weeks.

Conditions

Short Bowel Syndrome

Keywords

Drug Therapy

Outcome Measures

Primary Outcomes (11)

• Number of Participants With Treatment-emergent Adverse Events (TEAEs)

  An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. TEAEs were defined as any AEs whose onset occurred, severity worsened, or intensity increased after receiving the investigational product.

  From first dose of study drug until follow-up visit (4 weeks after end of treatment [EOT]/end of termination [ET] {up to 47.3-51.3 weeks})

• Number of Participants With Serious Adverse Events (SAEs)

  An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An SAE is defined as any untoward medical occurrence that at any dose: results in death, is life threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, leads to a congenital anomaly /birth defect, is the other important medical event.

  From first dose of study drug until follow-up visit (4 weeks after EOT/ET [up to 47.3-51.3 weeks])

• Number of Participants With Adverse Events of Special Interest (AESIs)

  An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AESI, whether serious or non-serious, is one of scientific and medical concern specific to the compound or program, for which ongoing monitoring and rapid communication by the investigator to the sponsor may be appropriate.

  From first dose of study drug until follow-up visit (4 weeks after EOT/ET [up to 47.3-51.3 weeks])

• Number of Participants With Clinically Significant Abnormalities in Vital Signs Reported as an Adverse Event

  Vital signs include systolic and diastolic blood pressure, heart rate and body temperature.

  From first dose of study drug until follow-up visit (4 weeks after EOT/ET [up to 47.3-51.3 weeks])

• Change From Baseline in Body Weight Z-Score at EOT

  A Z-score is the deviation of the value for an individual from the mean value of the reference population divided by the standard deviation for the reference population. Z-score indicates the number of standard deviations away from the mean. A Z-score of 0 is equal to the mean of a reference population (i.e., healthy, age and sex-matched individuals). According to WHO Child Growth Standards used for assessment of this outcome measure, a weight for age Z-score below -2 indicates underweight.

  Baseline, EOT (up to 47.3-51.3 weeks)

• Change From Baseline in Height Z-Score at EOT

  A Z-score is the deviation of the value for an individual from the mean value of the reference population divided by the standard deviation for the reference population. Z-score indicates the number of standard deviations away from the mean. A Z-score of 0 is equal to the mean of a reference population (i.e., healthy, age and sex-matched individuals). According to WHO Child Growth Standards used for assessment of this outcome measure, a height for age Z-score below -2 indicates stunted.

  Baseline, EOT (up to 47.3-51.3 weeks)

• Change From Baseline in Head Circumference Z-Score at EOT

  A Z-score is the deviation of the value for an individual from the mean value of the reference population divided by the standard deviation for the reference population. Z-score indicates the number of standard deviations away from the mean. A Z-score of 0 is equal to the mean of a reference population (i.e., healthy, age and sex-matched individuals). According to the Food and Nutrition Technical Assistance (FANTA) Guide to Anthropometry used for assessment of this outcome measure, a head circumference for age Z-score below -2 indicates small head circumference.

  Baseline, EOT (up to 47.3-51.3 weeks)

• Change From Baseline in Weight-for-Length Z-Score at EOT

  A Z-score is the deviation of the value for an individual from the mean value of the reference population divided by the standard deviation for the reference population. Z-score indicates the number of standard deviations away from the mean. A Z-score of 0 is equal to the mean of a reference population (i.e., healthy, age and sex-matched individuals). According to WHO Child Growth Standards used for assessment of this outcome measure, a weight for length Z-score below -2 indicates wasted (recent and severe weight loss).

  Baseline, EOT (up to 47.3-51.3 weeks)

• Number of Participants With Any Laboratory Safety Finding Reported as an Adverse Event

  Laboratory safety parameters included biochemistry, hematology, and urinalysis.

  From first dose of study drug until follow-up visit (4 weeks after EOT/ET [up to 47.3-51.3 weeks])

• Number of Participants With a Change in Urine Output Reported as an Adverse Event

  Urine and stool output was recorded and calculated in the output diary over a 48-hour period of parenteral support (PS) and enteral nutrition (EN) stability before every site visit and within 1 week of implementing a change in the PS prescription.

  From first dose of study drug until follow-up visit (4 weeks after EOT/ET [up to 47.3-51.3 weeks])

• Number of Participants With a Change in Stool Output Reported as an Adverse Event

  Urine and stool output was recorded and calculated in the output diary over a 48-hour period of PS and EN stability before every site visit and within 1 week of implementing a change in the PS prescription.

  From first dose of study drug until follow-up visit (4 weeks after EOT/ET [up to 47.3-51.3 weeks])

Secondary Outcomes (5)

• Change From Baseline in PS Volume

  Baseline, Cycle 1 = Week 1, 2, 4, 8, 12, 16, 20, 24, and EOT, Cycle 2: Week 0, 1, 2, 4, 8, 12, 16, 20, 24, and EOT, Cycle 3 = Week 0, 1, 2, and EOT and overall EOT (for up to 47.3-51.3 weeks) [cycle length=28 weeks]

• Percent Change From Baseline in PS Volume

  Baseline, Cycle 1 = Week 1, 2, 4, 8, 12, 16, 20, 24, and EOT, Cycle 2 = Week 0, 1, 2, 4, 8, 12, 16, 20, 24, and EOT, Cycle 3 = Week 0, 1, 2, and EOT and overall EOT (for up to 47.3-51.3 weeks) [cycle length=28 weeks]

• Number of Participants Who Demonstrate at Least 20 Percent (%) Reduction From Baseline in PS Volume

  Baseline, Cycle 1 = Week 1, 2, 4, 8, 12, 16, 20, 24, and EOT, Cycle 2 = Week 0, 1, 2, 4, 8, 12, 16, 20, 24, and EOT, Cycle 3 = Week 0, 1, 2, and EOT and overall EOT (for up to 47.3-51.3 weeks) [cycle length=28 weeks]

• Number of Participants Who Achieved Enteral Autonomy

  Cycle 1 = Week 1, 2, 4, 8, 12, 16, 20, 24, and EOT, Cycle 2 = Week 0, 1, 2, 4, 8, 12, 16, 20, 24, and EOT, Cycle 3 = Week 0, 1, 2, and EOT and overall EOT (for up to 47.3-51.3 weeks) [cycle length=28 weeks]

• Change From Baseline in Number of Days Per Week of PS Usage at EOT

  Baseline, Cycle 1 = Week 1, 2, 4, 8, 12, 16, 20, 24, and EOT, Cycle 2 = Week 0, 1, 2, 4, 8, 12, 16, 20, 24, and EOT, Cycle 3 = Week 0, 1, 2, and EOT, and overall EOT (for 47.3-51.3 weeks) [cycle length=28 weeks]

Study Arms (1)

Teduglutide 0.05 milligram per kilogram (mg/kg)

EXPERIMENTAL

Participants will receive teduglutide 0.05 milligram per kilogram \[mg/kg\] (0.025 mg/kg for participants with moderate or greater renal impairment) subcutaneous \[SC\] injection once daily in a 28-week treatment cycle consisting of a 24-week treatment period followed by a 4-week no treatment follow-up period for a maximum of 3 cycles.

Drug: Teduglutide

Interventions

Teduglutide DRUG

Teduglutide 0.05 mg/kg SC injection

Also known as: TAK-633

Teduglutide 0.05 milligram per kilogram (mg/kg)

Eligibility Criteria

• Age: 4 Months+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

• Male or female pediatric patient of corrected gestational age 4 months or older.
• Body weight at the time of screening and baseline visits of at least 5 kg and \<10 kg for participants with normal renal function or mild renal impairment (estimated glomerular filtration rate \>=50 mL/min/1.73 m\^2), OR at least 10 kg and \<20 kg for participants with moderate or greater renal impairment (estimated glomerular filtration rate \<50 mL/min/1.73 m\^2).
• Diagnosis of short bowel syndrome (SBS) with intestinal failure, defined as dependence on PS to provide at least 30% of fluid or caloric needs.
• Participants to have stable PS for at least 1 month prior to screening as assessed by the investigator. Stable PS is defined as inability to significantly reduce parenteral nutrition/intravenous fluid (PN/IV) support, usually associated with minimal or no advance in enteral feeds (ie, 10% or less change in PN or advance in feeds), assessed by the investigator.

You may not qualify if:

• A parent/guardian who is not capable of understanding or not willing to adhere to the study visit schedule and other protocol requirements.
• Clinically significant intestinal obstruction, active or recurrent pancreatic or biliary disease, or dysmotility that prevents the advancement of enteral intake.
• Severe, known dysmotility syndrome, such as pseudo-obstruction or persistent, severe, active gastroschisis-related dysmotility, that is the primary contributing factor to feeding intolerance and inability to reduce PS, prior to screening. Dysmotility is defined as severe if it is expected to limit the advancement of enteral feeding.
• Major gastrointestinal (GI) surgical intervention including significant intestinal resection or bowel lengthening procedure within 3 months prior to screening (insertion of feeding tube, anastomotic ulcer repair, minor intestinal resections =\<10 cm and endoscopic procedures are allowed).
• Cardiac disease that makes the patient vulnerable to changes in fluid status.
• History of cancer or known cancer predisposition syndrome, such as juvenile polyposis or Beckwith-Wiedemann syndrome, or first degree relative with early onset of GI cancer (including hepatobiliary and pancreatic cancer).
• Concurrent treatment with glucagon-like peptide-2 (GLP-2), human growth hormone, or analogs of these hormones within 6 months prior to the screening visit, or concurrent treatment with octreotide, or GLP-1 analogs within 30 days prior to the screening visit.
• Concurrent treatment with biological therapy (eg, anti-tumor necrosis factor \[anti-TNF\]) for active Crohn's disease within 6 months prior to the screening visit.
• Participation in a clinical study using an experimental drug (other than glutamine or omegaven) within 3 months or 5.5 half-lives of the experimental drug, whichever is longer, prior to the screening visit and for the duration of the study.
• Known or suspected intolerance or hypersensitivity to the study drug, closely related compounds, or any of the stated ingredients.
• Signs of active, severe, or unstable clinically significant hepatic impairment during the screening period as meeting at least 2 of any of the following parameters:
• International normalized ratio \>1.5 not corrected with parenteral vitamin K
• Platelet count \<100×10\^3/mcrL due to portal hypertension
• Presence of clinically significant gastric or esophageal varices
• Cirrhosis

Sponsors & Collaborators

• Takeda: lead

Study Sites (6)

University of Tsukuba Hospital

Tsukuba, Ibaraki, Japan

Location

Tohoku University Hospital

Sendai, Miyagi, Japan

Location

Showa University Hospital

Shinagawa-ku, Tokyo, Japan

Location

Akita University Hospital

Akita, Japan

Location

Kyushu University Hospital

Fukuoka, Japan

Location

Kagoshiha University Hospital

Kagoshima, Japan

Location

Related Publications (1)

• Masumoto K, Muto M, Sasaki T, Shikamura M, Tanaka T, Sakui S, Miyamoto M, Nakano H, Kondo T, Ieiri S. Teduglutide in pediatric patients under 10 kg with short bowel syndrome on parenteral support: An open-label study. Pediatr Int. 2026 Jan-Dec;68(1):e70301. doi: 10.1111/ped.70301.

  PMID: 41454663 DERIVED

Related Links

• To obtain more information on the study, click here/on this link.

MeSH Terms

Conditions

Short Bowel Syndrome

Interventions

teduglutide

Condition Hierarchy (Ancestors)

Malabsorption Syndromes; Intestinal Diseases; Gastrointestinal Diseases; Digestive System Diseases; Postoperative Complications; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Results Point of Contact

• Title: Study Director
• Organization: Takeda

TrialDisclosures@takeda.com

1-877-825-3327

Study Officials

• Medical Director

  Takeda

  STUDY DIRECTOR

Publication Agreements

• PI is Sponsor Employee: No
• Restriction Type: OTHER
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: August 26, 2021
• First Posted: August 30, 2021
• Study Start: January 4, 2022
• Primary Completion: September 27, 2023
• Study Completion: September 27, 2023
• Last Updated: May 16, 2024
• Results First Posted: May 16, 2024

Record last verified: 2024-05

Data Sharing

• IPD Sharing: Will not share

Locations

JP (6)